Search

Your search keyword '"Bewicke-Copley, Findlay"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Bewicke-Copley, Findlay" Remove constraint Author: "Bewicke-Copley, Findlay"
38 results on '"Bewicke-Copley, Findlay"'

Search Results

1. Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation

4. Transcriptomic analysis of cutaneous squamous cell carcinoma reveals a multigene prognostic signature associated with metastasis

5. Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma

7. CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.

8. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

9. The role of stress-derived vesicles in the bystander effect and cancer related cachexia

12. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

13. The Genomic Landscape of Actinic Keratosis

17. SCD inhibition eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy

18. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

19. Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

20. Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia

21. Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes

22. Germline ERCC excision repair 6 like 2 (ERCC6L2) mutations lead to impaired erythropoiesis and reshaping of the bone marrow microenvironment

23. CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia

26. Allele-Specific Expression of Leukemia Genes Is Associated with Pathogenicity in Poor Risk AML

27. The XPO1-FOXC1-HOX Functional Axis Opens New Therapeutic Avenues to Treat DEK-NUP214 AML Patients

29. Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia

31. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

32. Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma

34. Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel

35. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2Dmutant lymphomas

37. Meta-Analysis Using a Novel Database, miRStress, Reveals miRNAs That Are Frequently Associated with the Radiation and Hypoxia Stress-Responses

38. RNAi2015 - Ten years of RNAi Oxford.

Catalog

Books, media, physical & digital resources